Yesterday, Aprea’s stock was at $4.8. However, today it is gaining momentum after publishing some great news: the price is currently $5.45 in the pre-market, resulting in a 13% gain. The company today announced positive data from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML.
In 33 patients in the trial, the relapse-free survival (RFS) at 1-year post-transplant was 58% and the average RFS was 12.1 months. The overall survival (OS) at 1-year post-transplant was 79%, with an average OS of 19.3 months. In previous clinical trials evaluating post-transplant outcomes in TP53 mutant MDS and AML, patients have reported a 1-year post-transplant RFS of approximately 30% and a median OS of 5-8 months.
Moreover, the post-transplant regimen of eprenetapopt and azacitidine was well-handled among patients in the trial. The company schedules to discuss the data from this Phase 2 clinical trial with the U.S. Food and Drug Agency (FDA) in the second part of 2021 and expect to show data at future scientific or medical conferences.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.